UPCC 26424 An Analysis of Manufacturing Outcomes with Patient Factors from Multiple Myeloma Patients Prescribed Ciltacabtagene Autoleucel

Enrolling By Invitation
99 years or below
All
Phase N/A
1 Location

Brief description of study

The purpose of this study is to learn how participant factors (such as medical history and manufacturing starting material, also known as Apheresis) can predict successful manufacturing of ciltacabtagene autoleucel (Cilta-cel). This information can be used to potentially improve manufacturing processes and treat more patients with Cilta-cel.

We would like to rely on Sterling IRB as the IRB of record for this study.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 22 Apr 2026. Study ID: 24-0777
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator